Chemomab Therapeutics Ltd at Aegis Virtual Conference Transcript
For everyone tuning in, we have Chemomab Therapeutics. They trade on the Nasdaq under the ticker CMMB. And when management is ready to get started, you guys can kick us off. Thank you.
Welcome. I'm Dale Pfost, CEO of Chemomab. And we are delighted to be presenting at the Ageas Conference today. I'm joined today by Adi Mor, our Co-Founder and CSO, Matt Frankel, our CMO, and Don Marvin, our EVP, COO, and CFO. Please refer to our forward-looking statements and risk factors, including those on file with the SEC.
Here's why we're so excited about Chemomab, in four key points we'll cover today. We have a unique dual activity target with disease-modifying potential addressing fundamental mechanisms of fibro-inflammatory disease. We've worked towards derisking our programs through 10 years of extensive preclinical studies reinforced by four completed clinical trials.
We expect to have two Phase 2 readouts in 2024, and we're addressing lethal diseases with high unmet need that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
